{"id":1466,"date":"2023-07-10T09:01:27","date_gmt":"2023-07-10T09:01:27","guid":{"rendered":"https:\/\/healthynewsusa.com\/?p=1466"},"modified":"2023-07-10T09:01:30","modified_gmt":"2023-07-10T09:01:30","slug":"what-you-need-to-know-about-the-drug-price-fight-in-those-tv-ads","status":"publish","type":"post","link":"https:\/\/healthynewsusa.com\/?p=1466","title":{"rendered":"What You Need to Know About the Drug Price Fight in Those TV Ads"},"content":{"rendered":"
In recent months ominous ads about prescription drugs have flooded the TV airwaves. Perhaps by design, it\u2019s not always clear who\u2019s sponsoring the ads or why.<\/p>\n
Or, for that matter, why now?<\/p>\n
The short answer is that Congress is paying attention. House and Senate members from both parties have launched at least nine bills, parts of which may be packaged together this fall, that take aim at pharmacy benefit managers, companies that channel prescription drugs to patients. Here\u2019s a primer to help you decipher what\u2019s happening.<\/p>\n
What\u2019s the bottom line? While the PBMs\u2019 secrecy, ubiquity, and power make them a target of outrage, they generally operate on behalf of their customers, which are insurance plans and employers, whose goal is to hold down prices. The PBMs do that by extracting painful concessions, a double-edged sword.<\/p>\n
\u201cPBMs are the only thing we have to lower brand-name drug prices and prevent the drug industry from charging whatever they want,\u201d said Benjamin Rome, an internist and health policy researcher at Harvard Medical School.<\/p>\n
If those drug prices were 100% covered by insurance, that might sit fine with consumers, but it would further blow up health care spending, already nearly a fifth<\/a> of the economy. Hospitals, insurers, the drug industry, and PBMs all point fingers at one another to shift blame, but they all benefit from the system. The smarmy PBM guy in the suit may prevent you from getting the drug your doctor ordered, but that\u2019s only because the maker of another drug gave him \u2014 and therefore your insurance company \u2014 a better deal.<\/p>\n On the other hand, the vertical integration of the PBMs \u2014 an issue the Federal Trade Commission is studying but that is not the subject of any bill in Congress \u2014 enables unfair competition. \u201cMy concern with any bills is the unintended consequences,\u201d Rome said. \u201cWill the new structures they create be any better for patients?\u201d<\/p>\n KFF Health News<\/a> is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF\u2014an independent source of health policy research, polling, and journalism. Learn more about KFF<\/a>.<\/p>\nUSE OUR CONTENT<\/h3>\n